Перейти к содержимому
Bending the Curve Trial by Trial
?EN

Назад: Рак мочевого пузыря

Список литературы: Рак мочевого пузыря

130 источников, процитированных на этой странице. Ссылки ведут к первоисточнику.

  1. CASE RA, HOSKER ME, McDONALD DB, PEARSON JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med. 1954;11(2):75-104. PubMedDOI
    ЦитироватьЗагрузка…
  2. CASE RA, PEARSON JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. II. Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med. 1954;11(3):213-6. PubMedDOI
    ЦитироватьЗагрузка…
  3. WHITMORE WF Jr, MARSHALL VF. Radical total cystectomy for cancer of the bladder: 230 consecutive cases five years later. J Urol. 1962;87:853-68. PubMedDOI
    ЦитироватьЗагрузка…
  4. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-3. PubMedDOI
    ЦитироватьЗагрузка…
  5. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133(3):403-7. PubMedDOI
    ЦитироватьЗагрузка…
  6. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205-9. PubMedDOI
    ЦитироватьЗагрузка…
  7. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066-73. PubMedDOI
    ЦитироватьЗагрузка…
  8. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354(9178):533-40. PubMedDOI
    ЦитироватьЗагрузка…
  9. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-9. PubMedDOI
    ЦитироватьЗагрузка…
  10. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-77. PubMedDOI
    ЦитироватьЗагрузка…
  11. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-75. PubMedDOI
    ЦитироватьЗагрузка…
  12. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-70. PubMedDOI
    ЦитироватьЗагрузка…
  13. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927-34. PubMedDOI
    ЦитироватьЗагрузка…
  14. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66. PubMedDOI
    ЦитироватьЗагрузка…
  15. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186-90, quiz 2435. PubMedDOI
    ЦитироватьЗагрузка…
  16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202-5; discussion 205-6. PubMedDOI
    ЦитироватьЗагрузка…
  17. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005;2004(2):CD005246. PubMedDOI
    ЦитироватьЗагрузка…
  18. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-2. PubMedDOI
    ЦитироватьЗагрузка…
  19. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-8. PubMedDOI
    ЦитироватьЗагрузка…
  20. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3). PubMedDOI
    ЦитироватьЗагрузка…
  21. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45. PubMedDOI
    ЦитироватьЗагрузка…
  22. International Collaboration of Trialists, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-7. PubMedDOI
    ЦитироватьЗагрузка…
  23. Dietrich HG, Golka K. Bladder tumors and aromatic amines - historical milestones from Ludwig Rehn to Wilhelm Hueper. Front Biosci (Elite Ed). 2012;4(1):279-88. PubMedDOI
    ЦитироватьЗагрузка…
  24. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705-11. PubMedDOI
    ЦитироватьЗагрузка…
  25. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-88. PubMedDOI
    ЦитироватьЗагрузка…
  26. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801-9. PubMedDOI
    ЦитироватьЗагрузка…
  27. FDA. Accelerated approval letter, BLA 761034 (Tecentriq, atezolizumab), signed 18 May 2016. Источник
  28. Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016;34(16):1935-44. PubMedDOI
    ЦитироватьЗагрузка…
  29. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20. PubMedDOI
    ЦитироватьЗагрузка…
  30. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. PubMedDOI
    ЦитироватьЗагрузка…
  31. Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483-1492. PubMedDOI
    ЦитироватьЗагрузка…
  32. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015-1026. PubMedDOI
    ЦитироватьЗагрузка…
  33. FDA. Replacement approval letter, BLA 761069 (Imfinzi, durvalumab); the effective approval date remains 1 May 2017 (replacement letter corrects a manufacturing-facility error); includes accelerated approval requirements. Источник
  34. FDA. Accelerated approval letter, BLA 125514/S-017 (Keytruda, pembrolizumab; urothelial carcinoma ineligible for cisplatin), signed 18 May 2017. Источник
  35. FDA. Supplement approval letter, BLA 125514/S-018 (Keytruda, pembrolizumab; urothelial carcinoma after platinum-containing chemotherapy), signed 18 May 2017. Источник
  36. FDA. Tecentriq (atezolizumab) prescribing information, BLA 761034/S-001, revised 4/2017. Источник
  37. FDA. Accelerated approval letter, BLA 761034/S-001 (Tecentriq, atezolizumab; urothelial carcinoma in patients not eligible for cisplatin-containing chemotherapy), signed 17 April 2017. Источник
  38. Messing EM. The BCG Shortage. Bladder Cancer. 2017;3(3):227-228. PubMedDOI
    ЦитироватьЗагрузка…
  39. Ojerholm E, Smith A, Hwang WT, Baumann BC, Tucker KN, Lerner SP, et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017;123(5):794-801. PubMedDOI
    ЦитироватьЗагрузка…
  40. Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017;3(9):e172411. PubMedDOI
    ЦитироватьЗагрузка…
  41. Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-757. PubMedDOI
    ЦитироватьЗагрузка…
  42. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019;37(1):44-51. PubMedDOI
    ЦитироватьЗагрузка…
  43. FDA. Accelerated approval letter, NDA 212018 (Balversa, erdafitinib), signed 12 April 2019. Источник
  44. FDA. Accelerated approval letter, BLA 761137 (Padcev, enfortumab vedotin-ejfv), signed 18 December 2019. Источник
  45. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970-976. PubMedDOI
    ЦитироватьЗагрузка…
  46. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. PubMedDOI
    ЦитироватьЗагрузка…
  47. Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592-2600. PubMedDOI
    ЦитироватьЗагрузка…
  48. EMA. Bavencio (avelumab): European public assessment report page; lists first-line maintenance treatment of urothelial carcinoma among its indications; conditional marketing authorisation of 18 September 2017 switched to full authorisation on 19 August 2020 (page read 20 October 2026). Источник
  49. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 761049/S-009 (Bavencio, avelumab; maintenance treatment of urothelial carcinoma), signed 30 June 2020. Источник
  50. U.S. Food and Drug Administration. Supplement approval letter, BLA 125514/S-066, pembrolizumab (Keytruda), BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ; electronic signature 8 January 2020. Источник
  51. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. PubMedDOI
    ЦитироватьЗагрузка…
  52. Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(23):2658-2666. PubMedDOI
    ЦитироватьЗагрузка…
  53. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. PubMedDOI
    ЦитироватьЗагрузка…
  54. Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. PubMedDOI
    ЦитироватьЗагрузка…
  55. Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107-117. PubMedDOI
    ЦитироватьЗагрузка…
  56. FDA. Supplement approval letter, BLA 761069/S-029 (Imfinzi, durvalumab; removal of an indication previously approved under accelerated approval), signed 19 February 2021. Источник
  57. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 761137/S-006 and S-008 (Padcev, enfortumab vedotin-ejfv), signed 9 July 2021. Источник
  58. FDA. Supplement approval letter, BLA 761034/S-041 (Tecentriq, atezolizumab; removal of an indication previously approved under accelerated approval), signed 13 April 2021. Источник
  59. FDA. Accelerated approval letter, BLA 761115/S-009 (Trodelvy, sacituzumab govitecan-hziy; urothelial cancer), signed 13 April 2021. Источник
  60. U.S. Food and Drug Administration. Supplement approval letter, BLA 125554/S-097, Opdivo (nivolumab). e-signed 19 August 2021. Источник
  61. The Lancet Oncology. Correction to Lancet Oncol 2021; 22: 919-30 (correction to Balar AV et al., KEYNOTE-057). Lancet Oncol. 2021;22(8):e347. PMID 34339650; DOI 10.1016/S1470-2045(21)00414-9; read on thelancet.com 2026-10-30. PubMedDOIИсточник
  62. New England Journal of Medicine. Correction: Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma (correction to Bajorin DF et al., N Engl J Med 2021;384:2102-2114). N Engl J Med. 2021;385(9):864. Published 25 August 2021. PMID 34437799; DOI 10.1056/NEJMx210012; read on nejm.org 2026-10-30. PubMedDOIИсточник
  63. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. PubMedDOI
    ЦитироватьЗагрузка…
  64. Surlemont L, Nouhaud FX, Dupuis H, Delcourt C, Defortescu G, Cornu JN, et al. [BCG strain shortage from 2012 to 2014: Evaluation of its impact on the management of patients with high-risk NMIBC]. Prog Urol. 2021;31(6):324-331. PubMedDOI
    ЦитироватьЗагрузка…
  65. Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474-2485. PubMedDOI
    ЦитироватьЗагрузка…
  66. Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872-882. PubMedDOI
    ЦитироватьЗагрузка…
  67. European Medicines Agency. Opdivo: EPAR - Procedural steps taken and scientific information after authorisation (archive version), page 15. Variation II/0100, extension of indication to adjuvant monotherapy for adults with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression of 1% or more at high risk of recurrence after radical resection: CHMP opinion 24/02/2022, Commission decision 01/04/2022. Read 2026-10-31. Источник
  68. EMA. Padcev (enfortumab vedotin): European public assessment report page; opinion adopted 24 February 2022, marketing authorisation issued 13 April 2022 (page read 20 October 2026). Источник
  69. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. BLA approval letter, STN BL 125700/0, nadofaragene firadenovec-vncg (Adstiladrin), 16 December 2022. Источник
  70. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Summary Basis for Regulatory Action, STN BL 125700/0, nadofaragene firadenovec-vncg (Adstiladrin), 16 December 2022. Источник
  71. FDA. Tecentriq (atezolizumab) prescribing information, BLA 761034/S-050, revised 12/2022 (recent major changes: urothelial carcinoma accelerated approval indication removed). Источник
  72. FDA. Supplement approval and release from postmarketing requirement/commitment letter, BLA 761034/S-050 (Tecentriq, atezolizumab; withdrawal of the first-line metastatic urothelial carcinoma accelerated approval indication), signed 2 December 2022. Источник
  73. Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, et al. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Eur Urol. 2022;82(3):273-279. PubMedDOI
    ЦитироватьЗагрузка…
  74. Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244-258. PubMedDOI
  75. Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, et al. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid. 2023;2(1):EVIDoa2200167. PubMedDOI
    ЦитироватьЗагрузка…
  76. FDA. Accelerated approval letter, BLA 125514/S-136 (Keytruda, pembrolizumab, in combination with enfortumab vedotin), signed 3 April 2023. Источник
  77. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 125514/S-151 and S-152 (Keytruda, pembrolizumab with enfortumab vedotin-ejfv), signed 15 December 2023. Источник
  78. FDA. Accelerated approval letter, BLA 761137/S-018 (Padcev, enfortumab vedotin-ejfv, in combination with pembrolizumab), signed 3 April 2023. Источник
  79. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 761137/S-024 and S-025 (Padcev, enfortumab vedotin-ejfv with pembrolizumab), signed 15 December 2023. Источник
  80. Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023;389(21):1961-1971. PubMedDOI
    ЦитироватьЗагрузка…
  81. O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023;41(25):4107-4117. PubMedDOI
    ЦитироватьЗагрузка…
  82. EMA. Balversa (erdafitinib): European public assessment report page; opinion adopted 27 June 2024, marketing authorisation issued 22 August 2024 (page read 20 October 2026). Источник
  83. U.S. Food and Drug Administration. BLA approval letter, BLA 761336, nogapendekin alfa inbakicept-pmln (Anktiva); electronic signature 22 April 2024. Источник
  84. FDA. Supplement approval and fulfilment of postmarketing requirements letter, NDA 212018/S-007, S-008 and S-009 (Balversa, erdafitinib), signed 19 January 2024. Источник
  85. U.S. Food and Drug Administration. Supplement approval letter, BLA 125554/S-125, nivolumab (Opdivo) with cisplatin and gemcitabine, first-line unresectable or metastatic urothelial carcinoma; electronic signature 6 March 2024. Letter text read 21 October 2026. Источник
  86. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 761115/S-058 (Trodelvy, sacituzumab govitecan-hziy; voluntary withdrawal of the urothelial indication), signed 22 November 2024. Источник
  87. Maguire WF, Lee D, Weinstock C, Gao X, Bulik CC, Agrawal S, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2024;30(10):2011-2016. PubMedDOI
    ЦитироватьЗагрузка…
  88. Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720-730. PubMedDOI
    ЦитироватьЗагрузка…
  89. Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35(6):485-490. PubMedDOI
  90. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. PubMedDOI
    ЦитироватьЗагрузка…
  91. Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391(19):1773-1786. PubMedDOI
    ЦитироватьЗагрузка…
  92. Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35(1):107-117. PubMedDOI
    ЦитироватьЗагрузка…
  93. Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bögemann M, Simone G, et al. TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025;43(33):3578-3588. PubMedDOI
    ЦитироватьЗагрузка…
  94. U.S. Food and Drug Administration. NDA approval letter, NDA 219683, gemcitabine intravesical system (Inlexzo); electronic signature 9 September 2025. Источник
  95. U.S. Food and Drug Administration. NDA approval letter, NDA 215793, mitomycin for intravesical solution (Zusduri), recurrent low-grade intermediate-risk non-muscle invasive bladder cancer; electronic signature 12 June 2025. Letter text read 21 October 2026. Источник
  96. U.S. Food and Drug Administration. Supplement approval letter, BLA 761069/S-050, Imfinzi (durvalumab). e-signed 28 March 2025. Источник
  97. U.S. Food and Drug Administration. Supplement approval letter, BLA 125514/S-188, Keytruda (pembrolizumab). e-signed 21 November 2025. Источник
  98. U.S. Food and Drug Administration. Supplement approval letter, BLA 761137/S-032, Padcev (enfortumab vedotin). e-signed 21 November 2025. Источник
  99. Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol. 2025;43(1):15-21. PubMedDOI
    ЦитироватьЗагрузка…
  100. Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, et al. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial. Ann Oncol. 2025;36(10):1212-1219. PubMedDOI
    ЦитироватьЗагрузка…
  101. Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025;36(5):561-571. PubMedDOI
    ЦитироватьЗагрузка…
  102. Ballas LK, Solanki AA, Baumann BC, Dirix P, Hassanzadeh C, Zaorsky NG, et al. Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2026;. PubMedDOI
  103. Clark PE, Holzbeierlein J, Chang SS, Djaladat H, Kim SK, Kirkby E, et al. 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2026;:101097JU0000000000005280. PubMedDOI
  104. Cancer Research UK. Bladder cancer survival statistics. Health professional page. Accessed 21 October 2026; the page displays no update date. Источник
  105. ClinicalTrials.gov. NCT00024349 (BC2001). Registry record, accessed 20 October 2026. NCT00024349
  106. ClinicalTrials.gov. NCT02632409 (CheckMate 274). Registry record, accessed 20 October 2026. NCT02632409
  107. ClinicalTrials.gov. NCT03022825 (QUILT-3.032). Registry record, accessed 20 October 2026. NCT03022825
  108. ClinicalTrials.gov. NCT03711032 (KEYNOTE-676). Registry record, API v2, accessed 21 October 2026. NCT03711032
  109. ClinicalTrials.gov. NCT03732677 (NIAGARA). Registry record, accessed 20 October 2026. NCT03732677
  110. ClinicalTrials.gov. NCT03775265 (SWOG S1806). Registry record, API v2, accessed 21 October 2026. NCT03775265
  111. ClinicalTrials.gov. NCT03924895 (KEYNOTE-905/EV-303). Registry record, accessed 20 October 2026. NCT03924895
  112. ClinicalTrials.gov. NCT04241185 (KEYNOTE-992). Registry record, API v2, accessed 21 October 2026. NCT04241185
  113. ClinicalTrials.gov. NCT04700124 (KEYNOTE-B15/EV-304). Registry record, accessed 20 October 2026. NCT04700124
  114. ClinicalTrials.gov. NCT05538663 (BRIDGE (EA8212)). Registry record, API v2, accessed 21 October 2026. NCT05538663
  115. ClinicalTrials.gov. NCT05714202 (SunRISe-3). Registry record, API v2, accessed 21 October 2026. NCT05714202
  116. ClinicalTrials.gov. NCT05911295 (SGNDV-001 (DV-001)). Registry record, API v2, accessed 21 October 2026. NCT05911295
  117. EMA. Keytruda (pembrolizumab): European public assessment report page; its urothelial carcinoma indications include enfortumab vedotin combination first-line treatment (page read 20 October 2026). Источник
  118. EMA. Tecentriq (atezolizumab): European public assessment report page; lists a urothelial carcinoma monotherapy indication (page read 20 October 2026). Источник
  119. U.S. Food and Drug Administration. Supplement approval letter, BLA 761336/S-002, nogapendekin alfa inbakicept-pmln (Anktiva); electronic signature 14 October 2026. Источник
  120. U.S. Food and Drug Administration. Supplement approval letter, BLA 125514/S-194, Keytruda (pembrolizumab). e-signed 10 July 2026. Источник
  121. U.S. Food and Drug Administration. Supplement approval letter, BLA 761137/S-037, Padcev (enfortumab vedotin-ejfv). e-signed 10 July 2026. Источник
  122. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Источник
  123. FDA. Withdrawn | Cancer Accelerated Approvals. Listing, content current as of 5 October 2026 (accessed 19 October 2026). Источник
  124. Flaig TW, Spiess PE, Abern M, An Y, Bangs R, Begovic J, et al. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(5):186-203. PubMedDOI
  125. Galsky MD, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann Oncol. 2026;37(1):69-78. PubMedDOI
    ЦитироватьЗагрузка…
  126. Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, et al. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026;395(4):338-348. PubMedDOI
    ЦитироватьЗагрузка…
  127. Garrison-Morton-Norman History of Medicine (historyofmedicine.com). Entry for Ludwig Rehn, Blasengeschwülste bei Fuchsin-Arbeitern, Archiv für klinische Chirurgie 50:588-600, 1895 (entry 2128.1). Page last updated 14 July 2026. Источник
  128. Gontero P, Mariappan P, Pradere B, Rai BP, Liedberg F, Compérat E, et al. EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update. Eur Urol. 2026;90(4):389-412. PubMedDOI
  129. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Bladder Cancer. Page accessed 21 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Источник
  130. Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026;394(13):1257-1269. PubMedDOI
    ЦитироватьЗагрузка…